Hongtao Liu
Hematology · Madison, WINPI 1336332345
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Agios Pharmaceuticals, Inc. at 24.6% of the total. Reporting peaked in 2022 at $7,380 and has fallen 85.3% since, to $1,081 in 2025.
Across 51 payments — averaging $560.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$7K
- Servier Pharmaceuticals LLC$7K
- Incyte Corporation$5K
- Rigel Pharmaceuticals, Inc.$3K
- Pfizer$2K
- AbbVie$2K
- plus $2K from 11 others
Across 28 payments — averaging $17,065 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celularity Inc.$173K
- Novartis$155K
- AstraZeneca$45K
- Astellas Pharma Global Development$44K
- Karyopharm Therapeutics Inc.$35K
- Merck$25K
- plus $432 from 2 others
What the payments were for
- Consulting fees$16,85059%
- Speaking & faculty fees$7,90028%
- Travel & lodging$1,6556%
- Food & beverage$2,1628%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 11 | $7,038 |
| Servier Pharmaceuticals LLC | 8 | $7,003 |
| Incyte Corporation | 9 | $5,485 |
| Rigel Pharmaceuticals, Inc. | 5 | $3,075 |
| Pfizer | 1 | $2,000 |
| AbbVie | 3 | $1,500 |
| Daiichi Sankyo Inc. | 2 | $885 |
| Beigene, Ltd. | 1 | $450 |
| AstraZeneca | 2 | $259 |
| Johnson & Johnson | 1 | $141 |
| Beigene USA, Inc. | 1 | $134 |
| Stemline Therapeutics Inc. | 1 | $131 |
| Pharmaessentia USA Corporation | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 2 | $120 |
| Taiho Oncology, Inc. | 1 | $118 |
| Kyowa Kirin, Inc. | 1 | $108 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XospataGilteritinib Fumarate | 15 | $312,039 |
| JakafiRuxolitinib Phosphate | 12 | $209,487 |
| Fluconazole | 31 | $1,508 |
| Ursodiol | 23 | $1,098 |
| Imatinib Mesylate | 14 | $879 |
| Acyclovir | 61 | $717 |
| Levofloxacin | 32 | $330 |
| Ondansetron Hcl | 24 | $164 |
| Famotidine | 16 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $5,485 | $209,48712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other hematology in Madison
- John SheehanMadison$25K
- Julie ChangMadison$17K
- Natalie CallanderMadison$11K
- David YangMadison$136
- Savanah GisrielMadison$52
- Kim DittusMadison$23
- Bradford SchwartzMadison$0
- Eliot WilliamsMadison$0
- Christopher FletcherMadison$0
- Michael DeiningerMilwaukee$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.